IPP Bureau
Lupin receives approval from USFDA for Paliperidone extended-release tablets
By IPP Bureau - July 01, 2022
Paliperidone Extended-Release Tablets (RLD Invega) had estimated annual sales of USD 152 million in the U.S
Zydus receives final approval from USFDA for Lacosamide injection
By IPP Bureau - July 01, 2022
Lacosamide Injection is used to treat partial-onset seizures.
H Clinical adds commercial home health capabilities for pharma industry
By IPP Bureau - July 01, 2022
H Clinical is the leader in decentralized clinical trial support and home visits in Latin America
Akebia Therapeutics regaining rights to Vadadustat in the US, Europe and China
By IPP Bureau - July 01, 2022
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
Biologicals have emerged as a therapy of choice where traditional chemical drugs fail: Dr Bharati Pravin Pawar
By IPP Bureau - July 01, 2022
National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries
JB Pharma acquires 4 paediatric brands from Dr Reddy’s Laboratories
By IPP Bureau - July 01, 2022
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
NADMED brings first CE-marked NAD+ analysis kit to the market
By IPP Bureau - June 30, 2022
NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites
India’s first mRNA vaccine from Gennova gets DCGI approval
By IPP Bureau - June 30, 2022
It is a two dose vaccine to be administered intramuscularly at 28 days apart
TTK Healthcare launches e-Superstore - 'Love Depot'
By IPP Bureau - June 30, 2022
LoveDepot.com addresses this gap that is yawning in the market
Experts call for “Disability Inclusive Health Care System” to address health inequity
By IPP Bureau - June 30, 2022
We must try to make the health care system more accessible for people with disabilities
Weizmann’s study sheds new light on a promising antidepressant
By IPP Bureau - June 30, 2022
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
MTPA announces long-term findings from post-marketing safety study of Radicava
By IPP Bureau - June 30, 2022
Analysis of Post-Marketing Safety Data Shows Consistent Findings with Safety Profile Reported in Clinical Trials of Edaravone
Pfizer and BioNTech inks new agreement with US Government to provide additional doses of COVID-19 vaccine
By IPP Bureau - June 30, 2022
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
Dr. Reddy's Laboratories announces conclusion of patent litigation with Indivior
By IPP Bureau - June 30, 2022
The settlement and dismissal resolves all claims between the parties
Glenmark Pharmaceuticals expand its OTC portfolio
By IPP Bureau - June 29, 2022
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
